Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study.

导出原文传递

翻译打印收藏纠错

第一作者： Dominic G,Rothwell

第一单位： Clinical Experimental Pharmacology Group, CRUK Manchester Institute, Manchester, UK.

作者： Dominic G,Rothwell ^[1] ; Mahmood,Ayub ^[1] ; Natalie,Cook ^[2] ; Fiona,Thistlethwaite ^[3] ; Louise,Carter ^[2] ; Emma,Dean ^[3] ; Nigel,Smith ^[2] ; Shaun,Villa ^[3] ; Joanne,Dransfield ^[2] ; Alexandra,Clipson ^[3] ; Daniel,White ^[1] ; Kamrun,Nessa ^[2] ; Saba,Ferdous ^[3] ; Matthew,Howell ^[2] ; Avinash,Gupta ^[1] ; Bedirhan,Kilerci ^[1] ; Sumitra,Mohan ^[1] ; Kris,Frese ^[1] ; Sakshi,Gulati ^[1] ; Crispin,Miller ^[2] ; Allan,Jordan ^[1] ; Helen,Eaton ^[1] ; Nicholas,Hickson ^[1] ; Ciara,O'Brien ^[1] ; Donna,Graham ^[1] ; Claire,Kelly ^[4] ; Sreeja,Aruketty ^[5] ; Robert,Metcalf ^[5] ; Jaseela,Chiramel ^[2] ; Nadina,Tinsley ^[2] ; Alexander J,Vickers ^[2] ; Roopa,Kurup ^[2] ; Hannah,Frost ^[2] ; Julie,Stevenson ^[2] ; Siobhan,Southam ^[2] ; Dónal,Landers ^[2] ; Andrew,Wallace ^[2] ; Richard,Marais ^[2] ; Andrew M,Hughes ^[1] ; Ged,Brady ^[1] ; Caroline,Dive ^[1] ; Matthew G,Krebs ^[6]

作者单位： Clinical Experimental Pharmacology Group, CRUK Manchester Institute, Manchester, UK. ^[1] Experimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, UK. ^[2] Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. ^[3] Drug Discovery Unit, CRUK Manchester Institute, Manchester, UK. ^[4] North West Centre for Genomic Medicine, Manchester, UK. ^[5] Innovative Medicines Biotech Unit AstraZeneca, Cambridge, UK. ^[6] Molecular Oncology Group, CRUK Manchester Institute, Manchester, UK. ^[7] Clinical Experimental Pharmacology Group, CRUK Manchester Institute, Manchester, UK. caroline.dive@manchester.ac.uk. ^[8] Manchester Centre for Cancer Biomarker Sciences, University of Manchester, Manchester, UK. caroline.dive@manchester.ac.uk. ^[9] Experimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, UK. matthew.krebs@manchester.ac.uk. ^[10] Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. matthew.krebs@manchester.ac.uk. ^[11]